| Submission received | November 22, 2024 |
|---|---|
| Expert committee meeting (initial) | May 15, 2025 |
| Draft recommendation posted for stakeholder feedback | June 02, 2025 |
| End of feedback period | June 16, 2025 |
| Final recommendation posted | July 17, 2025 |
| CDA-AMC review report(s) posted | July 30, 2025 |
| Submission received | November 27, 2024 |
|---|---|
| Expert committee meeting (initial) | May 15, 2025 |
| Draft recommendation posted for stakeholder feedback | June 05, 2025 |
| End of feedback period | June 19, 2025 |
| Clarification: - Reconsideration: minor revisions requested by drug programs - Request for reconsideration accepted | |
| CDA-AMC review report(s) posted | August 05, 2025 |
| Submission received | November 22, 2024 |
|---|---|
| Expert committee meeting (initial) | May 15, 2025 |
| Draft recommendation posted for stakeholder feedback | June 05, 2025 |
| End of feedback period | June 19, 2025 |
| Final recommendation posted | July 28, 2025 |
| CDA-AMC review report(s) posted | July 28, 2025 |
| Call for patient/clinician input open | 21-Nov-24 |
|---|---|
| Call for patient/clinician input closed | 17-Jan-25 |
| Submission received | 07-Jan-25 |
| Submission accepted | 21-Jan-25 |
| Review initiated | 22-Jan-25 |
| Draft CADTH review report(s) provided to sponsor for comment | 09-Apr-25 |
| Deadline for sponsors comments | 22-Apr-25 |
| CDA-AMC review report(s) and responses to comments provided to sponsor | 15-May-25 |
| Expert committee meeting (initial) | 28-May-25 |
| Clarification: CDEC recommendation held pending receipt of NOC and evaluation of the finalized submission requirements | |
| Draft recommendation issued to sponsor | - |
| Draft recommendation posted for stakeholder feedback | - |
| End of feedback period | - |
| Call for patient/clinician input open | 15-Nov-24 |
|---|---|
| Call for patient/clinician input closed | 17-Jan-25 |
| Submission received | 03-Jan-25 |
| Submission accepted | 17-Jan-25 |
| Review initiated | 20-Jan-25 |
| Draft CADTH review report(s) provided to sponsor for comment | 11-Apr-25 |
| Deadline for sponsors comments | 24-Apr-25 |
| CDA-AMC review report(s) and responses to comments provided to sponsor | 15-May-25 |
| Expert committee meeting (initial) | 28-May-25 |
| Draft recommendation issued to sponsor | 11-Jun-25 |
| Draft recommendation posted for stakeholder feedback | 19-Jun-25 |
| End of feedback period | 04-Jul-25 |
| Clarification: - Reconsideration: major revisions requested by sponsor Target CDEC reconsideration meeting date to be determined | |
| Call for patient/clinician input open | November 12, 2024 |
|---|---|
| Call for patient/clinician input closed | January 10, 2025 |
| Submission received | December 20, 2024 |
| Submission accepted | January 13, 2025 |
| Review initiated | January 14, 2025 |
| Draft CADTH review report(s) provided to sponsor for comment | April 09, 2025 |
| Deadline for sponsors comments | April 22, 2025 |
| CDA-AMC review report(s) and responses to comments provided to sponsor | May 15, 2025 |
| Expert committee meeting (initial) | May 28, 2025 |
| Draft recommendation issued to sponsor | June 11, 2025 |
| Draft recommendation posted for stakeholder feedback | June 19, 2025 |
| End of feedback period | July 04, 2025 |
| Final recommendation issued to sponsor and drug plans | July 17, 2025 |
| Final recommendation posted | August 05, 2025 |
| Deadline for sponsor to submit redaction requests on draft CADTH review report(s) | July 31, 2025 |
| CDA-AMC review report(s) posted | - |
| Call for patient/clinician input open | November 07, 2024 |
|---|---|
| Call for patient/clinician input closed | January 06, 2025 |
| Submission received | December 19, 2024 |
| Submission accepted | January 13, 2025 |
| Clarification: - Submission was not accepted for review on 10 January 2025 | |
| Review initiated | January 14, 2025 |
| Clarification: - Submission temporarily suspended - Additional information has been received and the temporary suspension of the review has been lifted | |
| Draft CADTH review report(s) provided to sponsor for comment | April 28, 2025 |
| Deadline for sponsors comments | May 07, 2025 |
| CDA-AMC review report(s) and responses to comments provided to sponsor | May 30, 2025 |
| Expert committee meeting (initial) | June 11, 2025 |
| Draft recommendation issued to sponsor | June 23, 2025 To June 25, 2025 |
| Draft recommendation posted for stakeholder feedback | July 03, 2025 |
| End of feedback period | July 17, 2025 |
| Call for patient/clinician input open | November 07, 2024 |
|---|---|
| Call for patient/clinician input closed | January 06, 2025 |
| Submission received | December 18, 2024 |
| Submission accepted | January 09, 2025 |
| Review initiated | January 10, 2025 |
| Draft CADTH review report(s) provided to sponsor for comment | April 08, 2025 |
| Deadline for sponsors comments | April 17, 2025 |
| CDA-AMC review report(s) and responses to comments provided to sponsor | May 15, 2025 |
| Expert committee meeting (initial) | May 28, 2025 |
| Draft recommendation issued to sponsor | June 10, 2025 |
| Draft recommendation posted for stakeholder feedback | June 19, 2025 |
| End of feedback period | July 04, 2025 |
| Final recommendation issued to sponsor and drug plans | July 18, 2025 |
| Final recommendation posted | - |
| Deadline for sponsor to submit redaction requests on draft CADTH review report(s) | August 01, 2025 |
| CDA-AMC review report(s) posted | - |
Transparency is essential in economic modelling to make complex analyses more understandable, reliable, and actionable. We are taking a new step to increase the transparency around how we handle economic models that are submitted by a drug sponsor as part of a drug reimbursement review.